Case Report
Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
Figure 3
(a) Breast sections of CT scan before initiation of dabrafenib and trametinib. (b) Same section 2 weeks after treatment initiation. The arrow points to reduced mass and decreased pleural effusion.
| (a) |
| (b) |